Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676630 | 0.80 | CYP1A2 (0.44) | PDE4BHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL31704800 | 0.72 | KDM4E (0.48) | PDE4BHDAC8ALDH1A1PDE4DCOMT | |
| SCHEMBL17130043 | 0.72 | COMT (0.37) | HDAC8ALDH1A1COMTKDM4EPOLB | |
| SCHEMBL16834639 | 0.72 | KDM4E (0.48) | PDE4BHDAC8ALDH1A1PDE4DCOMT | |
| SCHEMBL31706246 | 0.71 | CHEK1 (0.39) | HDAC8ALDH1A1COMTKDM4EPOLB | |
| SCHEMBL21069616 | 0.71 | CCNC (0.45) | PDE4BHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL676174 | 0.71 | ALDH1A1 (0.51) | ALDH1A1KDM4E | |
| SCHEMBL3436257 | 0.70 | ALDH1A1 (0.56) | PDE4BHDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL1815535 | 0.70 | ALDH1A1 (0.51) | ALDH1A1COMTKDM4EPOLBGAA | |
| SCHEMBL287420 | 0.69 | ALDH1A1 (0.74) | PDE4BHDAC1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| EP-2303852-A2 | INHIBITORS OF AKT ACTIVITY | GlaxoSmithKline LLC (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009158374-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158374-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, PIK3CA | PDE4B 3289/4885HDAC1 766/4885HDAC8 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.